Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Table 1 Comparison of patient characteristics for overall and breast cancer subtypes

Character	Overall (number = 79)	mrTNBC (number = 18)	Luminal/HER2-negative (number = 41)	HER2-positive (number = 18)	P-value^a
Median age (range)	57 (30 to 77)	55 (30 to 65)	55 (39 to 76)	62 (51 to 70)	0.019
Performance status					0.046
0/1	58/21	14/4	32/9	11/7
Median time to the first PPV from recurrence, months (range)	35 (1.2 to 165)	8 (1.2 to 99)	40 (2 to 123)	55 (19 to 165)	0.101
Histopathology					0.079
Ductal carcinoma	71	16	37	17
Lobular carcinoma	4	1	2	1
Others	4	1	2
Positive status of HLA-A24	55	10	29	14	0.039
Positive status of HLA-A2	22	6	8	8	0.015
Visceral metastasis					0.009
Yes/No	60/19	8/6	29/11	16/2
Brain metastasis					0.002
Yes/No	11/68	3/11	2/38	6/12
Median duration of previous chemotherapies, months (range)	12 (2 to 148)	9 (4 to 43)	12 (2 to 9)	37 (10 to 148)	<0.0001
Usage of previous standard chemotherapy
Anthracycline	50	16	22	12	0.003
Taxane	58	16	24	17	0.0006
Trastuzumab	18		3	15	<0.0001
Regimen number of previous chemotherapies					0.008
<4/≥4	36/36	8/9	22/14	6/12
Combined therapies
Oral chemotherapy	19	5	8	6	0.060
Infusion chemotherapy	32	10	15	7	0.038
Anti-HER2 therapy	11			11	<0.0001
Hormonal therapy	23	2	17	4	0.006
Median times of peptide vaccination	14 (2 to 39)	12 (2 to 30)	15 (4 to 39)	12 (6 to 22)	0.021

^aThe Mann-Whitney U test and Fisher-Freeman-Halton exact test were performed to examine P-values for continuous values and categorical values. HER2, human epidermal growth factor 2; HLA, human leukocyte antigens; mrTNBC, metastatic recurrent triple-negative breast cancer; PPV, personalized peptide vaccination.

ISSN: 1465-542X